Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid neoplasm. Three subtypes have been identified by gene-expression studies; germinal center (GC) DLBCL, non-GC DLBCL, and ...

About 30 percent of all non-Hodgkin lymphoma diagnoses in the United States are DLBCL. Although it is an aggressive cancer that can spread quickly, it is treatable. These can be symptoms of many ...

It is also under assessment in the Phase II/III waveLINE-003 dose confirmation and expansion trial for relapsed or refractory DLBCL, and in the waveLINE-007 study in conjunction with R-CHP for ...

Managing R/R-transformed DLBCL remains a challenge, as affected patients have an approximate 27% chance of 4-year event-free survival and a 39% chance of overall survival. 2 Atezolizumab is a ...

While the grading scales used were different so no direct ... which is approved for DLBCL and another form of non-Hodgkin’s lymphoma called primary mediastinal large B-cell lymphoma (PMBCL ...

Why doesn't CAR-T cell therapy provide a lasting benefit for more patients with DLBCL? Cleveland Clinic's Brian Hill, MD, PhD delves into the issues. (2:51) Share on Facebook. Opens in a new tab ...

A study has shown that bortezomib can enhance the activity of doxorubicin-based chemotherapy for the treatment of activated B-cell-like (ABC) diffuse large B-cell lymphoma (DLBCL). This ...

Cytokine Release Syndrome, or CRS, of Grade 1 or 2 according to ASTCT grading was observed in 34. ... for the treatment of relapsed or refractory DLBCL after two or more lines of systemic therapy.